Daiichi Sankyo Inc.

Dec 12, 2017

Once-Daily, Oral SAVAYSA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Dec 01, 2017

Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization

Aug 31, 2017

Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108

Aug 31, 2017

Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain

Aug 31, 2017

Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108, for Acute Pain and Opioid-Induced Nausea and Vomiting

Aug 01, 2017

Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation

May 30, 2017

Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce Plans for Commercialization of RoxyBond(TM) (oxycodone hydrochloride) Tablets CII in the U.S.